NurExone Secures C$1.07 Million Through Private Placement to Advance Exosome Therapy Development

NurExone Biologic Inc. (NRX.V, NRXBF), a clinical-stage biopharmaceutical company, has successfully closed a non-brokered private placement, issuing 1.94 million units at C$0.55 per unit, generating approximately C$1.07 million in gross proceeds, pending final approval from the TSX Venture Exchange.

The company plans to allocate the funds toward general working capital requirements to support its ongoing operations and development initiatives.

Each unit issued comprises one common share and one common share purchase warrant. The warrants allow holders to acquire one additional common share at an exercise price of C$0.69 per share, remaining valid for 36 months from the closing date, with provisions for early acceleration.

Should the common shares achieve a 20-day volume-weighted average trading price (VWAP) of C$1.38 or higher on the TSX Venture Exchange, NurExone may elect to accelerate the warrants’ expiration. In such cases, warrant holders will be granted a 30-day window from the acceleration notice to exercise their rights. Failure to do so will result in the warrants expiring without value.

All securities issued through this offering remain subject to a statutory hold period of four months and one day from the closing date, concluding on December 21, 2026.

NurExone is dedicated to advancing regenerative exosome-based therapies targeting central nervous system injuries. Its lead investigational therapy, ExoPTEN, has demonstrated promising results in preclinical studies for treating acute spinal cord and optic nerve injuries.

Over the past year, NRX.V shares have fluctuated between C$0.43 and C$1.14. The stock concluded Thursday’s trading session at C$0.70, reflecting a 7.69% increase.

Source link